Tokyo Tape
Sign in
← Falco Holdings

Half-year report · Q2

4671.TEDINET S100UP43
Period2024-04-01 → 2024-09-30
Filed2024-11-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥21.4bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥43.0bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥21.3bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥974m2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥851m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥1.0bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥2.3bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥931m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥1.2bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥1.1bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥794m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.7bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥629m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥794m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥629m2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥36.2bnat 2024-09-30Cons.Assets
Total assets¥36.4bnat 2024-03-31Cons.Assets
Total assets¥36.7bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥10.2bnat 2024-09-30Cons.Liabilities
Total liabilities¥10.4bnat 2024-03-31Cons.Liabilities
Net assets / equity¥25.9bnat 2024-09-30Cons.Net assets
Net assets / equity¥26.0bnat 2024-03-31Cons.Net assets
Net assets / equity¥26.0bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥10.6bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥10.1bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥10.6bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥10.1bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥9.2bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥12.6bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥3.4bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥73m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.4bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥860m2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥4.5bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥3.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥74.462024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥151.722023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥56.292023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥74.252024-04-01 → 2024-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥150.92023-04-01 → 2024-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥56.142023-04-01 → 2023-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio71.4%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio71.2%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio70.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30¥0
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30¥0
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥176m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥13.1bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥13.1bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥0
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥726m
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥7.7bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥7.7bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥0
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥347m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥538m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥538m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥76m
—segment totalrevenue2024-04-01 → 2024-09-30¥21.4bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥21.4bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥0
—segment totalsegment profit2024-04-01 → 2024-09-30¥1.1bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30¥0
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30¥0
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥270m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥13.0bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.0bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥0
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥689m
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥0
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥385m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥449m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥449m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥46m
—segment totalrevenue2023-04-01 → 2023-09-30¥21.3bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥21.3bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥0
—segment totalsegment profit2023-04-01 → 2023-09-30¥1.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 522
ItemContextValueUnit
Provision for bonusesPrior1YearInstant496000000JPY
Provision for bonusesCurrentQuarterInstant510000000JPY
Other clPrior1YearInstant1975000000JPY
Other clCurrentQuarterInstant1892000000JPY
Current liabilitiesPrior1YearInstant7764000000JPY
Current liabilitiesCurrentQuarterInstant7684000000JPY
Net defined benefit liabilityPrior1YearInstant1760000000JPY
Net defined benefit liabilityCurrentQuarterInstant1717000000JPY
Asset retirement obligations nclPrior1YearInstant83000000JPY
Asset retirement obligations nclCurrentQuarterInstant83000000JPY
Other nclPrior1YearInstant790000000JPY
Other nclCurrentQuarterInstant762000000JPY
Noncurrent liabilitiesPrior1YearInstant2634000000JPY
Noncurrent liabilitiesCurrentQuarterInstant2564000000JPY
LiabilitiesPrior1YearInstant10398000000JPY
LiabilitiesCurrentQuarterInstant10248000000JPY
Capital stockPrior1YearInstant3371000000JPY
Capital stockCurrentQuarterInstant3371000000JPY
Capital surplusPrior1YearInstant3307000000JPY
Capital surplusCurrentQuarterInstant3307000000JPY
Retained earningsPrior1YearInstant19447000000JPY
Retained earningsCurrentQuarterInstant19441000000JPY
Treasury stockPrior1YearInstant-821000000JPY
Treasury stockCurrentQuarterInstant-821000000JPY
Shareholders equityPrior1YearInstant25305000000JPY
Shareholders equityCurrentQuarterInstant25299000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant642000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant538000000JPY
Valuation and translation adjustmentsPrior1YearInstant642000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant538000000JPY
Subscription rights to sharesPrior1YearInstant78000000JPY
Subscription rights to sharesCurrentQuarterInstant78000000JPY
Net assetsPrior1YearInstant26026000000JPY
Net assetsCurrentQuarterInstant25917000000JPY
Liabilities and net assetsPrior1YearInstant36425000000JPY
Liabilities and net assetsCurrentQuarterInstant36165000000JPY
Net salesPrior1YTDDuration21325000000JPY
Net salesCurrentYTDDuration21366000000JPY
Cost of salesPrior1YTDDuration14884000000JPY
Cost of salesCurrentYTDDuration14817000000JPY
Gross profitPrior1YTDDuration6440000000JPY
Gross profitCurrentYTDDuration6548000000JPY
Selling general and administrative expensesPrior1YTDDuration5589000000JPY
Selling general and administrative expensesCurrentYTDDuration5574000000JPY
Operating incomePrior1YTDDuration851000000JPY
Operating incomeCurrentYTDDuration974000000JPY
Dividends income noiPrior1YTDDuration55000000JPY
Dividends income noiCurrentYTDDuration48000000JPY
Reversal of allowance for doubtful accounts noiPrior1YTDDuration1000000JPY
Reversal of allowance for doubtful accounts noiCurrentYTDDuration0JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass